BI-0319

N/A

Report date: 2023/03/01 09:50:51
NME

Base Information

Drug NameBI-0319
Drug Alias NameBI-0319
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionFocal adhesion kinase 2 inhibitorsvon Hippel-Lindau disease tumor suppressor degraders
TargetsFocal adhesion kinase 2von Hippel-Lindau disease tumor suppressor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustria
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim Rcv Gmbh & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesBoehringer Ingelheim Rcv Gmbh & Co. Kg
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A